Biotech Values

[DewDiligence]

ADVM—The way I would interpret [today’s news] is the first cohort did not have significant enough efficacy (thus the dose escalation).

Dose escalation in this trial was preplanned until/unless DLT is encountered, so I don’t concur with your inference of subpar efficacy in the first cohort.

Moreover, all of the patients in this trial have had a positive response to conventional VEGF treatment and remain on such treatment during the trial, so evidence of incremental efficacy is going to be hard to come by.

p.s. I’m generally bearish on GT attempts in wet AMD, for the reason mentioned in #msg-113278211 (from 2015).